← Back to Screener
GridAI Technologies Corp. Common Stock (GRDX)
Price$2.79
Favorite Metrics
Price vs S&P 500 (26W)-53.59%
Price vs S&P 500 (4W)31.48%
Market Capitalization$9.38M
All Metrics
Book Value / Share (Quarterly)$33.09
Price vs S&P 500 (YTD)-42.12%
10-Day Avg Trading Volume0.11M
EPS (Annual)$-82447.68
Cash / Share (Quarterly)$0.99
Cash Flow / Share (Annual)$-5.82
P/B Ratio0.11x
P/B Ratio (Quarterly)0.09x
Net Income / Employee (Annual)$-29
Net Interest Coverage (TTM)-5812.09x
EPS Incl Extra (Annual)$-82447.68
Current Ratio (Annual)3.03x
Quick Ratio (Quarterly)2.60x
3-Month Avg Trading Volume0.12M
52-Week Price Return153.51%
Tangible BV / Share (Quarterly)$24.53
52-Week High$5.84
EPS Excl Extra (Annual)$-82447.68
26-Week Price Return-44.85%
Quick Ratio (Annual)3.03x
13-Week Price Return-25.32%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.62x
Enterprise Value$7.563
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.10
3-Month Return Std Dev121.76%
EPS Basic Excl Extra (Annual)$-82447.68
Total Debt / Equity (Quarterly)0.01x
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)118.41%
Year-to-Date Return-37.98%
5-Day Price Return42.36%
EPS Normalized (Annual)$-82447.68
Month-to-Date Return43.07%
EBITD / Share (Annual)$-82412.37
P/TBV (Quarterly)0.13x
P/B Ratio (Annual)0.04x
Book Value / Share (Annual)$36.48
Price vs S&P 500 (13W)-28.19%
Beta1.49x
52-Week Low$0.97
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.00
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GRDXGridAI Technologies Corp. Common Stock | — | — | — | — | $2.79 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
GridAI Technologies Corp is a late-stage biopharmaceutical company developing non-systemic therapies for gastrointestinal diseases. Key programs include latiglutenase for celiac disease (Phase 3-ready), capeserod for gastroparesis, and adrulipase for pancreatic insufficiency. The company focuses on addressing unmet medical needs in GI health.